PL3260128T3 - Zastosowanie medyczne rozpuszczalnego CD24 - Google Patents

Zastosowanie medyczne rozpuszczalnego CD24

Info

Publication number
PL3260128T3
PL3260128T3 PL17183045T PL17183045T PL3260128T3 PL 3260128 T3 PL3260128 T3 PL 3260128T3 PL 17183045 T PL17183045 T PL 17183045T PL 17183045 T PL17183045 T PL 17183045T PL 3260128 T3 PL3260128 T3 PL 3260128T3
Authority
PL
Poland
Prior art keywords
soluble
medical use
medical
Prior art date
Application number
PL17183045T
Other languages
English (en)
Inventor
Xincheng Zheng
Yang Liu
Wei Wu
Pan Zheng
Original Assignee
Oncoimmune, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune, Inc. filed Critical Oncoimmune, Inc.
Publication of PL3260128T3 publication Critical patent/PL3260128T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL17183045T 2010-04-28 2011-04-28 Zastosowanie medyczne rozpuszczalnego CD24 PL3260128T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32907810P 2010-04-28 2010-04-28
EP11778000.7A EP2563385B1 (en) 2010-04-28 2011-04-28 Methods of use of soluble cd24 for therapy of rheumatoid arthritis
PCT/US2011/034282 WO2011139820A1 (en) 2010-04-28 2011-04-28 Methods of use of soluble cd24 for therapy of rheumatoid arthritis
EP17183045.8A EP3260128B1 (en) 2010-04-28 2011-04-28 Medical use of soluble cd24

Publications (1)

Publication Number Publication Date
PL3260128T3 true PL3260128T3 (pl) 2021-02-08

Family

ID=44903987

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11778000T PL2563385T3 (pl) 2010-04-28 2011-04-28 Sposoby i zastosowanie rozpuszczalnego CD24 do terapii reumatoidalnego zapalenia stawów
PL17183045T PL3260128T3 (pl) 2010-04-28 2011-04-28 Zastosowanie medyczne rozpuszczalnego CD24

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL11778000T PL2563385T3 (pl) 2010-04-28 2011-04-28 Sposoby i zastosowanie rozpuszczalnego CD24 do terapii reumatoidalnego zapalenia stawów

Country Status (17)

Country Link
US (1) US8808697B2 (pl)
EP (3) EP2563385B1 (pl)
JP (5) JP5899206B2 (pl)
KR (1) KR20130086126A (pl)
CN (2) CN102869369B (pl)
AU (1) AU2011248540B2 (pl)
CA (1) CA2795823C (pl)
DK (1) DK2563385T3 (pl)
EA (2) EA027735B1 (pl)
ES (2) ES2645262T3 (pl)
IL (1) IL222739A0 (pl)
NO (1) NO2563385T3 (pl)
NZ (1) NZ603196A (pl)
PL (2) PL2563385T3 (pl)
PT (2) PT3260128T (pl)
SG (1) SG184907A1 (pl)
WO (1) WO2011139820A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
WO2016179456A1 (en) * 2015-05-07 2016-11-10 Oncoimmune, Inc. Use of cd24 for lowering low-density lipoprotein cholesterol levels
US10799558B2 (en) * 2016-02-02 2020-10-13 Oncoimmune, Inc. Use of CD24 proteins for treating leptin-deficient conditions
US10758574B2 (en) 2016-04-28 2020-09-01 The Board Of Trustees Of The Leland Stanford Junior University Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy
KR101789449B1 (ko) * 2016-12-08 2017-10-23 박문수 폐유지를 이용한 지방산 메틸에스테르 제조방법
JP2020510020A (ja) * 2017-03-07 2020-04-02 オンコイミューン， インコーポレイテッド 全身性エリテマトーデスを治療するために可溶性ｃｄ２４を使用する方法
CA3063894A1 (en) * 2017-05-15 2018-11-22 Oncoimmune, Inc. Methods of use of soluble cd24 for neuroprotection and remyelination
US11547741B2 (en) * 2017-05-22 2023-01-10 Oncoimmune, Inc. Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies
SG11202007815TA (en) * 2018-03-05 2020-09-29 Oncoimmune Inc Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)
AU2019269361C1 (en) * 2018-05-14 2025-06-12 Children's Research Institute, Children's National Medical Center Anti-CD24 compositions and uses thereof
MX2020013100A (es) * 2018-06-04 2021-02-17 Oncoimmune Inc Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis.
JP7728747B2 (ja) * 2019-08-23 2025-08-25 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ２４発現細胞およびそれらの用途
CN112480237B (zh) * 2019-09-12 2023-10-17 上海津曼特生物科技有限公司 一种融合蛋白及其制备方法和应用
AU2021386254A1 (en) * 2020-11-30 2023-06-29 Blaze Bioscience, Inc. Compositions and methods for selective depletion of target molecules
CN118076625A (zh) * 2021-09-28 2024-05-24 广州昂科免疫生物技术有限公司 包含071核心肽的融合蛋白及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5798448A (en) * 1994-10-27 1998-08-25 Genentech, Inc. AL-1 neurotrophic factor antibodies
CN101254302B (zh) * 1999-05-07 2011-05-11 杰南技术公司 使用与b细胞表面标志结合的拮抗剂治疗自身免疫病
US20030095966A1 (en) * 2000-03-29 2003-05-22 Yang Liu Method of blocking tissue destruction by autoreactive T cells
US20030106084A1 (en) * 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
WO2001072325A1 (en) * 2000-03-29 2001-10-04 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive t cells
KR20040074587A (ko) * 2001-02-19 2004-08-25 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 인공 단백질
US20050214290A1 (en) * 2001-03-29 2005-09-29 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
BR0211091A (pt) * 2001-07-13 2004-06-15 Merck Patent Gmbh Métodos para redução de imunogenicidade de polipeptìdeos
DK1569685T3 (da) * 2002-11-15 2012-11-12 Univ Colorado Regents Komplementmodulatorer rettet mod komplementreceptor-2
AU2007242919B8 (en) * 2003-04-09 2011-11-10 F. Hoffmann-La Roche Ag Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
MXPA05010778A (es) * 2003-04-09 2005-12-12 Genentech Inc Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa.
WO2005054810A2 (en) * 2003-11-26 2005-06-16 The Ohio State University Research Foundation Polymorphic cd24 genotypes that are predictive of multiple sclerosis risk and progression
WO2005113599A1 (en) * 2004-05-21 2005-12-01 Xencor, Inc. C1q family member proteins with altered immunogenicity
US20060160220A1 (en) * 2004-11-12 2006-07-20 Iogenetics Retroviral vectors with introns

Also Published As

Publication number Publication date
CA2795823A1 (en) 2011-11-10
JP6888221B2 (ja) 2021-06-16
ES2645262T3 (es) 2017-12-04
EP3260128B1 (en) 2020-07-29
KR20130086126A (ko) 2013-07-31
EP3260128A1 (en) 2017-12-27
PT3260128T (pt) 2020-10-22
EP2563385B1 (en) 2017-08-02
JP6526872B2 (ja) 2019-06-05
JP2017057216A (ja) 2017-03-23
EA036805B8 (ru) 2021-02-25
EA027735B1 (ru) 2017-08-31
CA2795823C (en) 2019-06-04
IL222739A0 (en) 2012-12-31
US8808697B2 (en) 2014-08-19
HK1176007A1 (zh) 2013-07-19
EA036805B1 (ru) 2020-12-23
ES2826445T3 (es) 2021-05-18
EA201790538A2 (ru) 2017-07-31
JP2019151655A (ja) 2019-09-12
EP2563385A1 (en) 2013-03-06
EA201290961A1 (ru) 2013-04-30
JP2013527168A (ja) 2013-06-27
JP6062502B2 (ja) 2017-01-18
DK2563385T3 (da) 2017-11-06
EP2563385A4 (en) 2013-10-02
CN102869369B (zh) 2016-05-18
CN105381451A (zh) 2016-03-09
CN105381451B (zh) 2021-03-09
PT2563385T (pt) 2017-11-10
JP2018127493A (ja) 2018-08-16
EA201790538A3 (ru) 2017-11-30
WO2011139820A1 (en) 2011-11-10
SG184907A1 (en) 2012-11-29
AU2011248540B2 (en) 2014-11-20
NZ603196A (en) 2014-07-25
PL2563385T3 (pl) 2018-04-30
JP2015187162A (ja) 2015-10-29
NO2563385T3 (pl) 2017-12-30
WO2011139820A8 (en) 2013-02-07
HK1222554A1 (zh) 2017-07-07
CN102869369A (zh) 2013-01-09
EP3845238A1 (en) 2021-07-07
JP5899206B2 (ja) 2016-04-06
US20130136739A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
PL3260128T3 (pl) Zastosowanie medyczne rozpuszczalnego CD24
EP2377457A4 (en) MEDICAL DEVICE
EP2531153A4 (en) MEDICAL DEVICE
GB201003817D0 (en) Medical device
GB201010193D0 (en) Medicinal use
ZA201302251B (en) Tissue fixator
FI20100377A0 (fi) Lääketieteellinen röntgenkuvauslaitteisto
FI20100180A7 (fi) Lääketieteellinen röntgenkuvauslaitteisto
EP2564796A4 (en) MEDICAL INSTRUMENT
AP2013006855A0 (en) Medical device
EP2641560A4 (en) SURGICAL PAD
ZA201304012B (en) Novel compound and medical use thereof
GB201005122D0 (en) Medical device
GB201004924D0 (en) Medical/cosmetic device
GB201015822D0 (en) Medical ruggedised case
GB201011411D0 (en) Therapeutic compounds and their use
IL232239A0 (en) Medical use
GB201205189D0 (en) Novel medical use
GB201015828D0 (en) Medical advice
GB201215502D0 (en) Medical use
GB201016461D0 (en) Medical instrument
PT2566579E (pt) Dispositivo médico para magnetoterapia
GB201001364D0 (en) New compounds and medical uses
GB201001370D0 (en) New compounds and medical uses
GB201001376D0 (en) New compounds and medical uses